Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Pharmaceuticals
Bristol-Myers Squibb Allies With Adnexus
March 5, 2007
| A version of this story appeared in
Volume 85, Issue 10
Bristol-Myers Squibb and Adnexus Therapeutics will work together to discover and develop protein-based oncology therapies. Adnexus will apply its PROfusion protein design technology in up to six research programs to identify drug candidates. Called adnectins, these candidates will be culled from a proprietary protein class based on fibronectin, an extracellular protein abundant in human serum. BMS will provide $30 million in upfront fees and research funding over the next three years and be responsible for development and commercialization.
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X